 Cisplatin CDDP is a major compound in chemotherapy in patients with non-small cell lung cancer NSCLC, small cell lung cancer SCLC and malignant mesothelioma. Cisplatin is associated with a number of side-effects, one of which is neurotoxicity. For a number of patients this neurotoxicity is a dose-limiting side-effect. At this point no measures are taken to prevent the occurrence of neurotoxicity during treatment with cisplatin. Recent studies have shown that the association of anti-oxidants to the treatment with cisplatin has a neuroprotective effect without loss of anti-tumour efficacy of cisplatin. One of these anti-oxidants is glutathione GSH, this is a natural anti-oxidant that is synthesized in all cells, mainly in the liver and the muscles. This GSH plays a central role in the pathophysiology of efficacy and of side-effects of cisplatin. We want to investigate the efficacy of N-acetylcysteine NAC, which serves as a substrate for the synthesis of GSH, in the prevention of cisplatin-induced neurotoxicity. 